Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering

Stem Cells

Volumn 30, Issue 12, 2012, Pages 2720-2731

  Yao, Longbiao ^a   Heuser Baker, Janet ^a   Herlea Pana, Oana ^a   Iida, Ryuji ^a   Wang, Qilong ^b   Zou, Ming Hui ^b   Barlic Dicen, Jana ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis regression; Bone marrow endothelial progenitors; CXCR4 antagonist AMD3100

Indexed keywords

CHOLESTEROL; GREEN FLUORESCENT PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLERIXAFOR; POLYINOSINIC POLYCYTIDYLIC ACID; TRIACYLGLYCEROL;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CELL REGENERATION; CELL THERAPY; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; GENE; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REMISSION; STEM CELL MOBILIZATION; TIE2 GENE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; BONE MARROW CELLS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; STEM CELL TRANSPLANTATION; STEM CELLS; VASODILATION;

MUS;

EID: 84870387394     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1256     Document Type: Article

References (65)

1. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006;6:508-519.
2. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24-33.
3. Nicholls SJ, Ballantyne CM, Barter PJ et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-2087.
4. Feig JE, Parathath S, Rong JX et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011;123:989-998.
5. Lieu HD, Withycombe SK, Walker Q et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation 2003;107:1315-1321.
6. Bailey AS, Jiang S, Afentoulis M et al. Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells. Blood 2004;103:13-19.
7. Pelosi E, Valtieri M, Coppola S et al. Identification of the hemangioblast in postnatal life. Blood 2002;100:3203-3208.
8. Grant MB, May WS, Caballero S et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002;8:607-612.
9. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005;106:1525-1531.
10. + hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007;27:1572-1579.
11. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228.
12. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-1236.
13. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
14. Urbich C, Aicher A, Heeschen C et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-742.
15. Shantsila E, Watson T, Tse HF et al. New insights on endothelial progenitor cell subpopulations and their angiogenic properties. J Am Coll Cardiol 2008;51:669-671.
16. Greenspan P, Fowler SD. Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res 1985;26:781-789.
17. Greenspan P, Mayer EP, Fowler SD. Nile red: A selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985;100:965-973.
18. Gladwin MT, Raat NJH, Shiva S et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol 2006;291:H2026-H2035.
19. Kelm M, Preik-Steinhoff H, Preik M et al. Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: Evidence for biochemical assessment of the endothelial L-arginine-NO pathway. Cardiovasc Res 1999;41:765-772.
20. Zeballos GA, Bernstein RD, Thompson CI et al. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation 1995;91:2982-2988.
21. Malte K. Nitric oxide metabolism and breakdown. Biochim Biophys Acta - Bioenergetics 1999;1411:273-289.
22. Russell A, Watts S. Vascular reactivity of isolated thoracic aorta of the C57BL/6J mouse. J Pharmacol Exp Ther 2000;294:598-604.
23. Rosenfeld ME, Averill MM, Bennett BJ et al. Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets 2008;9:210-216.
24. Siddique A, Shantsila E, Lip G et al. Endothelial progenitor cells: What use for the cardiologist? J Angiogenes Res 2010;2:6.
25. Umemura T, Higashi Y. Endothelial progenitor cells: Therapeutic target for cardiovascular diseases. J Pharmacol Sci 2008;108:1-6.
26. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004;95:343-353.
27. Gomes AL, Carvalho T, Serpa J et al. Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis. Blood 2010;115:3886-3894.
28. Croce G, Passacquale G, Necozione S et al. Nonpharmacological treatment of hypercholesterolemia increases circulating endothelial progenitor cell population in adults. Arterioscler Thromb Vasc Biol 2006;26:e38-e39.
29. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-2890.
30. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-3024.
31. Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000;97:3422-3427.
32. Sprengers RW, Lips DJ, Moll FL et al. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg 2008;247:411-420.
33. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-1595.
34. Yoder MC, Ingram DA. Endothelial progenitor cell: Ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol 2009;16:269-273.
35. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-1318.
36. Yin Y, Huang L, Zhao X et al. AMD3100 mobilizes endothelial progenitor cells in mice, but inhibits its biological functions by blocking an autocrine/paracrine regulatory loop of stromal cell derived factor-1 in vitro. J Cardiovasc Pharmacol 2007;50:61-67.
37. Capoccia BJ, Shepherd RM, Link DC. G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 2006;108:2438-2445.
38. Jujo K, Hamada H, Iwakura A et al. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci USA 2010;107:11008-11013.
39. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010;128:509-518.
40. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
41. Flomenberg N, Comenzo RL, Badel K et al. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant 2010;16:695-700.
42. Schlaeger TM, Bartunkova S, Lawitts JA et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997;94:3058-3063.
43. Motoike T, Loughna S, Perens E et al. Universal GFP reporter for the study of vascular development. Genesis 2000;28:75-81.
44. Jones CP, Pitchford SC, Lloyd CM et al. CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airways remodeling. Stem Cells 2009;27:3074-3081.
45. Qin G, Ii M, Silver M et al. Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med 2006;203:153-163.
46. Jin H, Aiyer A, Su J et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 2006;116:652-662.
47. Forstermann U. Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008;5:338-349.
48. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis 2004;15:235-242.
49. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005;97:1232-1235.
50. Bian K, Doursout MF, Murad F. Vascular system: Role of nitric oxide in cardiovascular diseases. J Clin Hypertens 2008;10:304-310.
51. Chavakis E, Dimmeler S. Homing of progenitor cells to ischemic tissues. Antioxid Redox Signal 2011;15:967-980.
52. Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events. Circulation 2005;111:2981-2987.
53. Sen S, McDonald SP, Coates PT et al. Endothelial progenitor cells: Novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond) 2011;120:263-283.
54. Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007;49:741-752.
55. Arai M, Misao Y, Nagai H et al. Granulocyte colony-stimulating factor a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006;70:1093-1098.
56. Lucerna M, Zernecke A, de Nooijer R et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out miceby promoting de novo leukocyte recruitment. Blood 2007;109:122-129.
57. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003;108:457-463.
58. George J, Afek A, Abashidze A et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005;25:2636-2641.
59. Hristov M, Zernecke A, Bidzhekov K et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007;100:590-597.
60. Phillips T, Childs AC, Dreon DM et al. A dietary supplement attenuates IL-6 and CRP after eccentric exercise in untrained males. Med Sci Sports Exerc 2003;35:2032-2037.
61. Colbert LH, Visser M, Simonsick EM et al. Physical activity, exercise, and inflammatory markers in older adults: Findings from the health, aging and body composition study. J Am Geriatr Soc 2004;52:1098-1104.
62. Shepherd RM, Capoccia BJ, Devine SM et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006;108:3662-3667.
63. Körbling M, Reuben J, Gao H et al. Recombinant human granulocyte colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: A novel blood cell component for therapeutic vasculogenesis. Transfusion 2006;46:1795-1802.
64. Cottle TE, Fier CJ, Donadieu J et al. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol 2002;39:134-140.
65. Mueller MM, Bialleck H, Bomke B et al. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: Results of a prospective longitudinal 5-year follow-up study. Vox Sang 2012; doi: 10.1111/j.1423-0410.2012.01632.x